FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2987696184> ?p ?o ?g. }

• W2987696184 abstract "Abstract Time to first exacerbation of cGVHD was reported recently as a prognostic risk factor for survival in a study of 96 patients (pts) by Kim et al. (doi:10.1038/sj.bmt.1705806). Pts with exacerbation of cGVHD experienced worse survival and higher nonrelapse mortality (NRM) compared to pts with no exacerbation. This association was particularly notable among pts with earlier onset of exacerbation. We conducted a retrospective study to validate these findings in 738 consecutive pts with cGVHD diagnosed after 5/1/01 without a prior history of recurrent or persistent malignancy after allogeneic hematopoietic cell transplantation. Pts had cGVHD according to NIH criteria, and the dataset did not include pts with persistent, recurrent or delayed onset of acute GVHD. Dates and the reasons for subsequent change of treatment after the initial treatment for cGVHD have been prospectively recorded since 05/01/01. Change of treatment is defined as addition of a new treatment for control of cGVHD, increased dose of corticosteroids to at least 1 mg/kg every other day for control of cGVHD, or addition of a topical immunosuppressive medication for treatment of a previously unaffected site. Change of treatment because of toxicity alone was not included, since the focus of the study was to use change of treatment as a surrogate marker for inadequate control of cGVHD. Fifty-six percent (397/738) of pts had a change of treatment for one or more of the following reasons: progressive signs or symptoms of cGVHD (n = 214), new site (n = 190), unimproved or persistent cGVHD (n = 118) or physician preference (n = 5). The median interval time to change of treatment was 3.8 months (range, 0.1–54), and 75% of the changes occurred within 9.1 months after the initial treatment. In time-dependent Cox proportional hazards regression models, change of treatment was associated with an increase in risk of NRM compared to pts without change of treatment [hazard ratio (HR), 2.14; 95% C.I, 1.5–3.1; p < 0.0001]. The HR for change of treatment within 4 months was 2.40 (95% C.I., 1.7–3.4), and the HR for a change of treatment beyond 4 months was 1.51 (95% C.I., 0.9–2.5). Thus, relative to a change of treatment within 4 months of cGVHD diagnosis, the increase in NRM associated with change in treatment after 4 months was somewhat attenuated (HR, 0.63; 95% C.I., 0.5–1.0; p = 0.05). Risk factors that were significant for changing treatment were skin involvement at diagnosis (HR, 1.31; 95% C.I, 1.0 – 1.7; p = 0.02), use of growth-factor mobilized blood cells for transplantation (HR, 1.41; 95% C.I, 1.0 – 1.9; p = 0.03), male recipient with female donor (HR, 1.26; 95% C.I, 1.0 – 1.6; p = 0.04), and HLA-mismatched recipient (HR, 1.32; 95% C.I, 1.0 – 1.7; p = 0.05). Changing treatment was strongly associated with decreased survival (HR, 3.82; 95% C.I. 2.8–5.2; p < 0.0001), but not with decreased risk of recurrent malignancy (HR = 0.80; 95% C.I., 0.5–1.3; p = 0.38). Our results show that a change of treatment is associated with increased risk of NRM, and that this increase may not be greatly affected by the time at which the change of treatment is made. The association of a change in treatment with increased NRM suggests that a first change of treatment at any time could be used as an indicator of unfavorable outcome in double-blind clinical trials of treatment for cGVHD." @default.
• W2987696184 created "2019-11-22" @default.
• W2987696184 creator A5013130893 @default.
• W2987696184 creator A5016644532 @default.
• W2987696184 creator A5017588406 @default.
• W2987696184 creator A5017952176 @default.
• W2987696184 creator A5031390636 @default.
• W2987696184 creator A5031463705 @default.
• W2987696184 creator A5057721855 @default.
• W2987696184 creator A5058926927 @default.
• W2987696184 creator A5059063645 @default.
• W2987696184 creator A5060476768 @default.
• W2987696184 creator A5060993908 @default.
• W2987696184 creator A5062054752 @default.
• W2987696184 creator A5070467855 @default.
• W2987696184 date "2007-11-16" @default.
• W2987696184 modified "2023-10-01" @default.
• W2987696184 title "Change of Treatment for Control of Chronic Graft-Versus-Host Disease (cGVHD) as a Time-Dependent Covariate for Nonrelapse Mortality and Survival." @default.
• W2987696184 doi "https://doi.org/10.1182/blood.v110.11.833.833" @default.
• W2987696184 hasPublicationYear "2007" @default.
• W2987696184 type Work @default.
• W2987696184 sameAs 2987696184 @default.
• W2987696184 citedByCount "0" @default.
• W2987696184 crossrefType "journal-article" @default.
• W2987696184 hasAuthorship W2987696184A5013130893 @default.
• W2987696184 hasAuthorship W2987696184A5016644532 @default.
• W2987696184 hasAuthorship W2987696184A5017588406 @default.
• W2987696184 hasAuthorship W2987696184A5017952176 @default.
• W2987696184 hasAuthorship W2987696184A5031390636 @default.
• W2987696184 hasAuthorship W2987696184A5031463705 @default.
• W2987696184 hasAuthorship W2987696184A5057721855 @default.
• W2987696184 hasAuthorship W2987696184A5058926927 @default.
• W2987696184 hasAuthorship W2987696184A5059063645 @default.
• W2987696184 hasAuthorship W2987696184A5060476768 @default.
• W2987696184 hasAuthorship W2987696184A5060993908 @default.
• W2987696184 hasAuthorship W2987696184A5062054752 @default.
• W2987696184 hasAuthorship W2987696184A5070467855 @default.
• W2987696184 hasConcept C120665830 @default.
• W2987696184 hasConcept C121332964 @default.
• W2987696184 hasConcept C126322002 @default.
• W2987696184 hasConcept C141071460 @default.
• W2987696184 hasConcept C167135981 @default.
• W2987696184 hasConcept C2777014857 @default.
• W2987696184 hasConcept C2777408962 @default.
• W2987696184 hasConcept C2779399171 @default.
• W2987696184 hasConcept C2779972918 @default.
• W2987696184 hasConcept C2911091166 @default.
• W2987696184 hasConcept C61511704 @default.
• W2987696184 hasConcept C71924100 @default.
• W2987696184 hasConcept C90924648 @default.
• W2987696184 hasConceptScore W2987696184C120665830 @default.
• W2987696184 hasConceptScore W2987696184C121332964 @default.
• W2987696184 hasConceptScore W2987696184C126322002 @default.
• W2987696184 hasConceptScore W2987696184C141071460 @default.
• W2987696184 hasConceptScore W2987696184C167135981 @default.
• W2987696184 hasConceptScore W2987696184C2777014857 @default.
• W2987696184 hasConceptScore W2987696184C2777408962 @default.
• W2987696184 hasConceptScore W2987696184C2779399171 @default.
• W2987696184 hasConceptScore W2987696184C2779972918 @default.
• W2987696184 hasConceptScore W2987696184C2911091166 @default.
• W2987696184 hasConceptScore W2987696184C61511704 @default.
• W2987696184 hasConceptScore W2987696184C71924100 @default.
• W2987696184 hasConceptScore W2987696184C90924648 @default.
• W2987696184 hasLocation W29876961841 @default.
• W2987696184 hasOpenAccess W2987696184 @default.
• W2987696184 hasPrimaryLocation W29876961841 @default.
• W2987696184 hasRelatedWork W1041259088 @default.
• W2987696184 hasRelatedWork W2080932452 @default.
• W2987696184 hasRelatedWork W2533558478 @default.
• W2987696184 hasRelatedWork W2559999242 @default.
• W2987696184 hasRelatedWork W2884628875 @default.
• W2987696184 hasRelatedWork W2911103373 @default.
• W2987696184 hasRelatedWork W2914752722 @default.
• W2987696184 hasRelatedWork W2979689417 @default.
• W2987696184 hasRelatedWork W4221128712 @default.
• W2987696184 hasRelatedWork W4283727911 @default.
• W2987696184 isParatext "false" @default.
• W2987696184 isRetracted "false" @default.
• W2987696184 magId "2987696184" @default.
• W2987696184 workType "article" @default.